Medilink has developed ADC-related technologies with independent intellectual property rights, where the indications have covered the top 10 tumor fields in terms of morbidity and mortality.
The following table summarizes the development status of our drug candidates and each drug candidate as of the latest practicable date:
Project
Target
Indications
Platform
Collaboration
Discovery
Pre -Clinical
IND
Phase 1
Phase 2
Phase 3
BLA
B7H3
Solid Tumor
YL202
HER3
Solid Tumor
BioNTech
YL203
Undisclosed
Solid Tumor
Evopoint
YL204
Undisclosed
Solid Tumor
Evopoint
YL205
Undisclosed
Solid Tumor
YL211
C-MET
Solid Tumor
Roche
YL212
DLL3
Solid Tumor
Zai Lab
YL215
MSLN
Solid Tumor
Harbour
YL221
EGFR
Solid Tumor
Henlius
YL222
PDL1
Solid Tumor
Henlius
YL216 | YL217 YL218
Undisclosed
Solid Tumor
YL231 | LYL232 YL233 | YL234
Undisclosed
Solid Tumor